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Background: The efficacies of tricuspid valve repair, risk factors for treatment failure and postoperative quality of
life have not been thoroughly evaluated in patients with tricuspid insufficiency associated with rheumatic heart
disease (RHD). We therefore reviewed our experience with ring and non-ring tricuspid annuloplasty for the treatment
of functional tricuspid insufficiency (TI) in RHD.
Methods: This retrospective, follow-up study involved 74 RHD patients who underwent either non-ring annuloplasty
(De Vega procedure; 34 patients, 45.95 %) or ring annuloplasty (40 patients, 54.05 %) along with concurrent mitral
or/and aortic valve replacement. Operation time, cardiopulmonary bypass time, aortic clamping time, intensive care
unit stay and extubation time were recorded. Echocardiographic findings and Short Form (SF)-36 scores were
compared between the two groups.
Results: In hospital mortality and complications were similar in the two study groups (P = 0.6755). At 1 week,
1 month, 6 months, 1 year, 2 years and even longer after the operation, the Kaplan–Meier curve of freedom
from mild and above recurrent TI showed significantly better efficacy in the ring annuloplasty group than the
De Vega procedure group (log rank P = 0.0377). Risk factors for recurrent TI included high pulmonary artery
systolic pressure (PASP) and non-ring annuloplasty (PASP: hazard ratio = 1.52; non-ring: hazard ratio = 1.42). The
mental component summary score at 1 year after the operation did not significantly differ between the two
groups (P = 0.6446), but the physical component summary score was significantly better in the ring annuloplasty
group (P = 0.0037).
Conclusion: Compared with non-ring annuloplasty, ring annuloplasty was associated with improved survival,
decreased TI recurrence and higher quality of life in RHD patients undergoing tricuspid valve repair combined
with mitral and/or aortic valve replacement.
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Despite the recent dramatic decline in rheumatic fever
in developed countries, rheumatic heart disease (RHD)
is still associated with significant morbidity and mortal-
ity in developing countries which accounts for more
than 200,000 deaths annually [1]. Without treatment,
the tricuspid valve insufficiency in RHD patients may
worsen over time, leading to severe symptoms, advanced* Correspondence: hxyyxxgwk@126.com
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insufficiency (TI) secondary to left heart lesions such as
chronic mitral or/and aortic valve disease, which causes
pulmonary hypertension, right ventricular volume over-
load, is mostly functional in nature and was associated
with annular dilation/remodeling. Therefore, correction
of the left heart lesion and strengthening of the tricuspid
annulus in this situation removes the impetus for pro-
gressive insufficiency [3].
Tricuspid valve repair is beneficial for treating severe TI
in patients requiring mitral valve surgery, according to the
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which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Ren et al. Journal of Cardiothoracic Surgery  (2015) 10:81 Page 2 of 7American Heart Association for the management of
patients with valvular heart disease [4]. Recently, bicuspi-
dization has since been superseded by other techniques
that aim to remodel the annulus by maintaining a trileaf-
let valve with a more physiological and stable annulus
[5]. “Non-ring” annuloplasties (such as the De Vega and
Peri-Guard procedures) have the advantages of simplicity
and low cost; however, some longitudinal studies have
showed a higher risk of recurrent TI after the De Vega
techniques than after ring annuloplasty [6]. Novel tech-
niques of tricuspid valve repair include the use of flexible
and rigid prosthetic rings or three-dimensional rings, and
flexible prosthetic bands [7]. According to Tang et al., the
advantages of rigid or flexible prosthetic rings may be
related to the prevention of annular dilation, right ven-
tricular volume overload and right ventricular failure [8].
Although studies on the repair of functional TI have
shown potential advantages of ring annuloplasty [9], the
efficacy of these techniques in rheumatic TI, the risk
factors for treatment failure and the resultant quality of
life have not yet been thoroughly evaluated.
The purpose of this study was therefore to review our
experience with patients who had undergone different
tricuspid valve repair procedures (De Vega procedure or
ring annuloplasty) for the treatment of TI.Methods
Patients
From March 2009 to September 2012, a total of 74
patients diagnosed with valve disease of rheumatic eti-
ology, significant heart failure (New York Heart Associ-
ation [NYHA] class, II–IV) and marked TI underwent
tricuspid annuloplasty, which was performed by the same
surgeon, in our institution. There were 11 male patients
and 63 female patients, whose ages ranged from 33 to
66 years (mean, 48.4 years). All patients underwent pre-
operative echocardiography during the 3 months preced-
ing the surgery. The De Vega procedure was performed in
34 (45.95 %) patients, and Cosgrove-Edwards flexible
bands (Edwards Lifesciences, Irvine, California, United
States) were used in 40 (54.05 %) patients. All the TIs were
functional, so patients with tricuspid stenosis, leaflet
calcification or severe leaflet thickening were excluded
from our analysis. Preoperative, operative and postop-
erative data were collected into a professional database.
All patients provided informed consent for inclusion in
the study. The study protocol was approved by the ethics
committee of our hospital.
Prior to the surgery, echocardiographic assessments
were performed to grade the severity of TI according
to color Doppler flow criteria [8], evaluate ventricular
function and estimate pulmonary artery systolic pres-
sure (PASP) on continuous Doppler scanning [10].Operative techniques
All tricuspid valve surgery was performed after concomi-
tant cardiac procedures, including aortic and/or mitral
valve surgery with median sternotomy and moderately
hypothermic cardiopulmonary bypass (CPB). Tricuspid
valve repair was performed under cardiac arrest. In the
case of the De Vega technique, a 2–0 pledget-supported
Ethibond mattress suture (Ethibond Excel 2–0 sutures,
Johnson & Johnson Intl., USA) was placed at the junction
of the annulus and right ventricular free wall, running
from the anteroseptal commissure to the posteroseptal
commissure [11]. This operation was performed in our
hospital until June 2010. Since June 2010, we switched to
ring annuloplasty, which employs multiple interrupted,
pledgeted 2–0 Ethibond sutures placed at the atrioannular
junction. After the flexible band was placed, the sutures
were tied [12]. All prosthetic valves (left-sided valve re-
placement) were St. Jude Medical (SJM) mechanical pros-
thesis (St. Jude Medical, St. Paul. Mn, USA).
Follow-up
All surviving patients were followed up at 1 week,
1 month, 1 year, 2 years and even longer after the sur-
gery. All follow-up data were collected on a data collec-
tion sheet and entered into a professional database
between March 2009 and March 2014. Postoperative
echocardiogram reports were available for all patients
(1 week, 1 month, 6 months, 1 year and 2 years after the
operation). The mean follow-up was 2.83 years (range,
2–4 years). Follow up of 94.6 % was achieved. Follow-up
was performed via telephone interviews and the collec-
tion of echocardiographic data.
The primary clinical end points of this study were de-
fined as the all-cause mortality rate and operative-related
or cardiac-related severe morbidity rates. The secondary
clinical end point was recurrent TI on postoperative echo-
cardiographic examination.
Quality of life
The Short Form (SF)-36 Health Survey is one of the
most extensive, standardized, self-administered, generic
questionnaires produced within the framework of the
International Quality of Life Assessment [13, 14]. The
responses to each question on the survey were summed
and transformed to give eight scores between 0 and 100,
with higher scores indicating a better state. We collected
the SF-36 questionnaires (in Chinese) before and at 1 year
after the surgery [15].
Statistical analysis
Categorical variables (Fisher exact test) were expressed
as percentages, and continuous variables (Student t-test)
were expressed as mean ± standard deviation. The Wil-
coxon rank sum test was used for variables with non-









Age (yr ± SD) 47.2 ± 7.3 49.5 ± 8.7 0.241
Male 7 20.6 % 4 10.0 % 0.326
Preoperative NYHA
ClassIII-IV
33 97.1 % 38 95.0 % 0.945
Preoperative TI grade
None (n) 0 0.0 % 0 0.0 % 0.131
Mild (n) 8 23.5 % 14 35.0 %
Moderate (n) 18 52.9 % 23 57.5 %
Severe (n) 8 23.5 % 3 7.5 %
Preoperative TS 0 0 0 0
Preoperative mitral
valve disease
None (n) 0 0.0 % 0 0.0 % 0.808
Stenosis (n) 21 61.7 % 24 60.0 %
Insufficiency (n) 2 5.8 % 4 10.0 %
Stenosis and insufficiency (n) 11 32.4 % 12 30.0 %
Preoperative aortic valve
disease
None (n) 17 50.0 % 21 52.5 % 0.98
Stenosis (n) 1 2.9 % 1 2.5 %
Insufficiency (n) 7 20.6 % 9 22.5 %
Stenosis and insufficiency (n) 9 26.5 % 9 22.5 %
Preoperative
LVEF 55.9 ± 9.1 58.1 ± 7.1 0.253
RVD 22.9 ± 5.1 21.9 ± 3.4 0.29
LVD 49.6 ± 6.66 47.9 ± 8.8 0.351
PASP 51.5 ± 16.6 49.9 ± 14.2 0.668
1 year Postoperative
LVEF 61.9 ± 10.0 61.0 ± 8.8 0.733
RVD 20.7 ± 2.9 20.0 ± 2.2 0.277
LVD 44.5 ± 5.6 45.6 ± 4.1 0.37
PASP 36.5 ± 7.4 36.0 ± 8.3 0.903
Concomitant procedures
MVR (n) 22 64.7 % 32 80.0 % 0.132
AVR (n) 0 0 0 0
MVR + AVR (n) 12 35.3 % 8 20.0 %
AVR aortic valve replacement, LVEF left ventricular ejection fraction, LVD left
ventricular diameter, RVD right ventricular diameter, MVR mitral valve
replacement, NYHA New York Heart Association, PASP pulmonary arterial
systolic pressure, SD standard deviation, TI tricuspid valve insuffiency,
TS tricuspid valve stenosis
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cluding mild, moderate and severe degree TI) were com-
pared using the Kaplan–Meier curve and log-rank test.
Significance was assumed for P < 0.05. We performed
mixed-model repeated-measures analysis and longitudinal
ordinal logistic regression for each tricuspid annuloplasty
technique. To determine the risk factors for postoperative
TI recurrence, we performed multivariate Cox regression.
All statistical analyses were performed using the Statis-




The preoperative and surgical characteristics of the pa-
tients are shown in Table 1. The two groups were well
matched and similar with regard to all pretreatment
characteristics. Furthermore, no significant difference was
found between the groups in terms of age, NYHA class,
left atrial size, left ventricular ejection fraction, PASP, and
occurrence rate of TI.
CPB, aortic clamping time and intensive care unit stay
The mean aortic clamping time in all patients was 88.0 ±
25.9 min. It was slightly, but not significantly, shorter
in the ring annuloplasty group (86.9 ± 25.3 min) than in
the De Vega procedure group (89.3 ± 26.8 min; P = 0.897).
The mean CPB time was 125.7 ± 31.2 min in the ring
annuloplasty group and 125.3 ± 31.0 min in De Vega
procedure group (P = 0.701). In addition, the duration of
intensive care unit stay and extubation time did not
significantly differ between the two study groups (ICU
stay P = 0.471, extubation time P = 0.610).
Mortality, reoperations and complications
The 30-day mortality rate was 2.9 % (one patient) in the
non-ring annuloplasty (De Vega procedure) group; the
cause of death was sudden cardiac arrest. In addition,
there were three late deaths: one cardiac failure and two
severe bleeding associated with warfarin. In the ring
annuloplasty group, one patient (2.5 %) died of cardiac
rupture within 30 days after the surgery, and there was
one late death that was caused by warfarin overdose.
The Kaplan–Meier survival rates were 88.2 % at 2 years
in the De Vega procedure group and 95.0 % in the ring
annuloplasty group (Fig. 1a, log rank P = 0.6755). In two
patients, severe postoperative complications occurred:
reoperation due to surgical bleeding (one patient, ring
annuloplasty group) and atrioventricular dissociation
requiring pacemaker implantation (one patient, ring
annuloplasty group). The rate of severe postoperative
complications was slightly, but not significantly, greater
in the ring annuloplasty group (5.8 %) than in the De
Vega procedure group (0 %; P = 0.208).Evaluation of tricuspid annuloplasty
To determine the overall efficacy of the two annulo-
plasty techniques, we determined the TI grade at the last
follow-up and assessed freedom from recurrence of
Fig. 1 Kaplan–Meier curves after surgery. a Survival curves in the
De Vega procedure group and the ring annuloplasty group. (log rank
P = 0.6755) b Freedom from mild and above recurrence of tricuspid
insufficiency in the De Vega procedure group and the ring
annuloplasty group. (log rank P = 0.0377) c Freedom from
moderate-to-severe recurrence of tricuspid insufficiency in the
De Vega procedure group and the ring annuloplasty group
(log rank P = 0.0970)
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degree TI by using the Kaplan–Meier survival curve
(Fig. 1b, c) from 1 week to more than 2 years after the
operation.
At 1 week after the operation, the overall TI recurrence
(including Mild degree above) differed significantly be-
tween the two groups (45.5 % in the De Vega procedure
group, 17.5 % in the ring annuloplasty group; P <0.01).But the moderate-to-severe TI recurrence was compar-
able among each group (2.9 % in the De Vega procedure
group, 2.5 % in the ring annuloplasty group; P = 0.907),
Meanwhile, decreased PASP and anteroposterior diame-
ters of the right atrium and right ventricle were observed
in both groups, but not significant (P > 0.05). At 1 month
after the operation, TI recurrence (including Mild degree
above) was also significantly higher in the De Vega pro-
cedure group (46.4 %) than in the ring annuloplasty
group (23.5 %; P = 0.030). Meanwhile the moderate-to-
severe TI recurrence was just equal to the data at 1 week
after the operation (2.9 % in the De Vega procedure
group, 2.5 % in the ring annuloplasty group; P = 0.907).
The decrease in PASP and anteroposterior diameters of
the right atrium and ventricle was similar in both groups
(P > 0.05). At 1 year postoperatively, the rate of TI recur-
rence (including mild degree or above) was still signifi-
cantly greater in the De Vega procedure group (58.0 %)
than in the ring annuloplasty group (27.5 %; P < 0.001),
and the rate of moderate-to-severe TI recurrence was
significantly more common in the De Vega procedure
group (17.6 %) than in the ring annuloplasty group
(2.5 %; P = 0.043). None of the patients had severe TI at
this time. At 2 years postoperatively, among all the alive
patients, mild, moderate and severe TI were present in
59.3 %, 18.0 % and 0 % patients, respectively, in the De
Vega procedure group and 42.3 %, 2.7 % and 0 % pa-
tients, respectively, in the ring annuloplasty group. The
rate of moderate-to-severe TI recurrence was still signifi-
cantly more common in the De Vega procedure group
(18.0 %) than in the ring annuloplasty group (2.7 %) Both
in terms of efficacy and duration, ring annuloplasty sur-
passed the De Vega procedure for the treatment of
functional TI associated with RHD.
Risk factors for TI recurrence
The following variables were entered in the multivari-
ate Cox regression model to identify significant inde-
pendent predictors of survival and event-free survival:
type of tricuspid valve repair surgery, age, gender, pre-
operative NYHA class, preoperative PASP, preoperative
right ventricular dysfunction, preoperative TI, tricuspid
valve repair type, preoperative mitral insufficiency or/and
stenosis, preoperative left ventricular ejection fraction,
concomitant mitral valve surgery and concomitant aortic
valve surgery. According to the Cox model, annuloplasty
type (De Vega procedure) and high preoperative PASP
were risk factors for TI recurrence (including mild to
severe TI; Table 2). Low left ventricular ejection fraction
was also a risk factor for TI recurrence. In patients with
better left heart function, preoperative TI may indicate a
greater degree of valve dysfunction, such as annular dila-
tion or valve tethering, which may hamper tricuspid valve
repair. Preoperative and follow-up NYHA classes were
Table 2 Multivariate regression analysis of the risk factors for
TI recurrence
Variable B value P value Hazard ratio SE
Preoperative PASP 0.51 0.018 1.52 0.22
Non-ring Annuloplasty,
(De Vega procedure)
0.46 0.051 1.47 0.24
PASP pulmonary arterial systolic pressure, SE standard error, TI tricuspid
insufficiency
Table 3 Comparison of pre-and postoperative SF-36 scores
between the ring and non-ring annuloplasty groups
Domain and summary scores De Vega
procedure
Ring annuloplasty
Physical Functioning Pre 33.60 ± 10.86 34.67 ± 15.31
Post 46.11 ± 13.84 52.67 ± 11.04
P Value <0.001 <0.001
Role-physical Problem Pre 30.34 ± 15.38 32.92 ± 13.00
Post 49.65 ± 14.17 53.75 ± 14.37
P Value <0.001 <0.001
Body Pain Pre 47.46 ± 16.04 47.78 ± 14.00
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tricular dysfunction (high right ventricular diameter and
body edema) was not a risk factor for TI recurrence.Post 51.16 ± 15.32 52.22 ± 12.75
P Value 0.320 0.204
General Health Perception Pre 39.31 ± 9.19 38.17 ± 15.95
Post 46.39 ± 13.29 51.67 ± 11.32
P Value <0.001 <0.001
Vitality Pre 42.17 ± 9.16 43.89 ± 11.28
Post 46.83 ± 10.87 49.17 ± 9.90
P Value 0.077 0.038
Social Functioning Pre 35.67 ± 9.44 37.50 ± 9.52
Post 46.17 ± 9.35 47.08 ± 9.66
P Value <0.001 <0.001
Role-emotional Problem Pre 45.18 ± 9.65 43.51 ± 14.64
Post 57.4 ± 13.71 53.70 ± 11.42
P Value <0.001 0.002
Mental Health Pre 47.00 ± 14.36 37.78 ± 12.16
Post 48.17 ± 13.29 45.97 ± 14.48
P Value 0.745 0.011
PCS Pre 38.61 ± 6.55 38.38 ± 8.34
Post 47.40 ± 6.97 52.58 ± 6.89
P Value <0.001 <0.001
MCS Pre 42.50 ± 5.69 40.67 ± 5.73Quality of life assessment
The preoperative parameters on the SF-36 scale did not
significantly differ between the two groups (physical func-
tioning, P = 0.917; role-physical, P = 0.555; bodily pain,
P = 0.216; general health, P = 0.592; vitality, P = 0.416; so-
cial functioning, P = 0.085; role-emotional, P = 0.332; men-
tal health, P = 0.142). At the 1-year follow-up, the mean
physical component summary (PCS) score was signifi-
cantly higher in the ring annuloplasty group (52.58 ±
1.258) than in the De Vega procedure group (47.40 ±
1.163; P = 0.0037). The mean mental component summary
(MCS) score did not significantly differ between the De
Vega procedure group (49.64 ± 1.048) and the ring annu-
loplasty group (48.98 ± 0.9682; P = 0.6446).
The comparison of the pre- and postoperative data
between the two study groups has been shown in Table 3.
Subgroup analysis revealed that patients in the De Vega
procedure group experienced significant improvement in
five of the eight health domains on the SF-36: physical
functioning, role-physical, general health, social function-
ing and role-emotional. Meanwhile, the ring annuloplasty
group patients experienced significant improvement in all
health domains, except for bodily pain (P = 0.204).Post 49.64 ± 5.74 48.98 ± 5.81
P Value <0.001 <0.001
MCS mental component summary, PCS physical component summary. Bold
face numbers shows the P < 0.05Discussion
Most studies of tricuspid valve repair have focused on
the indications for intervention, the technique of sur-
gery, survival rates and reoperation rates [10, 16]. Few
studies have evaluated the clinical outcomes and quality
of life after tricuspid valve annuloplasty in RHD patients
[17]. Functional TI with concomitant left-sided lesions,
such as mitral or aortic valve disease in RHD, is associ-
ated with high mortality and increased risk of adverse
events. In the western region of China, TI associated
with RHD often occurs in younger patients (in our
study, the mean age was 48.4 years) than does TI related
to other causes. Our study has shown that although the
use of a prosthetic ring did not significantly decrease
the incidence of adverse clinical outcomes and mid-
term mortality, it effectively alleviated TI recurrence andimproved the quality of life in patients with rheumatic
mitral and/or aortic valve disease.
Bernal et al. believed that annuloplasty rings were
more effective than the De Vega procedure in preventing
late TI after mitral valve repair for RHD [6]. Our study
also demonstrated that ring annuloplasty had more effi-
cacies in restoring and maintaining tricuspid valve func-
tion immediate after surgery, this result also duplicated
in 1 month, 1 year and 2 years follow-up which indicat-
ing annuloplasty is a more durable method for TI repair.
Different from patient with degenerated heart valve
disease, left-sided valve of RHD is often too difficult to
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valve tissue. As show in our study, all the patients re-
ceived prosthetic mitral valve replacement rather than
repair, which could completely change the native ring
structure and subsequently to some extend affect the
geometric shape of native tricuspid annulus. In this con-
dition, rather than constricting of the dilated tricuspid
annulus, better maintaining its geometric shape through
an annuloplasty ring may be of paramount importance
to ensure a durable repair effect. Also, in rheumatic
mitral valve disease, left atrial pressure and PASP increase
over time in nearly all patients; this leads to pressure
overload of the right ventricle and induces right ventricu-
lar enlargement [18]. If the PASP is markedly increased,
or the annulus moderately dilated, relatively minor leaflet
disease may lead to functional TI [19]. RHD patients tend
to have poor right heart function even before the occur-
rence of functional TI; therefore, the correction of even
mild or moderate TI in these patients necessitates a more
stable and durable annuloplasty method. Thus, the pros-
thetic ring technique may be selected as primary choose
for the correction of functional TI in RHD patients. In
our study, the multivariate Cox regression model re-
vealed that high preoperative PASP and non-ring annulo-
plasty had a negative impact on rate of freedom from TI
recurrence.
SF-36 scale is a validated measure of the overall phys-
ical and mental health status, though it does not contain
disease-specific questions [20]. To our best knowledge,
our study is the first to provide information on changes
in the quality of life of patients after tricuspid valve
repair surgery [21, 22]. An important goal of interven-
tions is to provide a subjective sense of satisfaction with
the treatment. The results of our study demonstrate that
quality of life was significantly improved 1 year after the
surgery as for both group. However, according to the
PCS score, the extent of postoperative physical improve-
ment in health significantly differed between the two
groups. Meanwhile, compared with the De Vega proced-
ure, the ring annuloplasty group patients experienced
more improvement in almost all health domains of SF-36
scale. These results suggest that the fewer TI recurrence
may cause a better symptom, such as fewer edema or
hepatic congestion after the surgery, which affect the sub-
jective sense of patients [19]. These trends require further
research, particularly, with regard to their effects on long-
term clinical outcomes.
The limitations of this study include its single-center
design and retrospective nature, with all of the inherent
limitations of such investigations. A non-randomized
study with short duration and small sample size may
generate potential bias. Moreover, we did not record and
analyze the diameter of the tricuspid annulus because
this data was not routinely recorded in our hospital.Nevertheless, our results may help cardiac surgeons
select an appropriate repair technique for the treatment
of tricuspid insufficiency due to rheumatic heart valve
disease.
Conclusion
Ring annuloplasty was more effective than the De Vega
procedure in treating functional TI in RHD patients
undergoing tricuspid valve repair combined with mitral
and/or aortic valve replacement. Our study suggests that
tricuspid valve repair surgery, especially ring annuloplasty,
significantly improved the quality of life of the patients.
These findings indicate that prosthetic ring annuloplasty
for the correction of functional TI in RHD may provide a
greater improvement in mid-term clinical outcomes
and quality of life than non-ring annuloplasty (De Vega
procedure).
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